Últimas noticias sobre Moleculin Biotech (NASDAQ:MBRX) Bolsa

Moleculin Biotech

Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

APPS

AVGR

BBAI

COHR

DGLY

FORM

MBRX

MTRX

PTIX

RANI

RXRX

SBET

Market Index Target Term Securities Linked To The Dow Jones Industrial Average

SLXN

SWKS

Coherent sorprende con sus resultados trimestrales y dispara sus acciones un 15,5%. ¿Qué otras empresas se mueven en el premercado de EE.UU.?

Acciones de Coherent (COHR) se disparan un 15%; 20 acciones que se mueven en el premercado de EE.UU.

Moleculin Biotech Inc

JP Morgan analyst Doug Anmuth <a target="_blank" href="https://www.benzinga.com/quote/PTON/analyst-ratings" rel="noreferrer noopener">reiterated the Neutral rating </a>on Peloton Interactive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTON#NASDAQ">PTON</a>).
The company reported a second-quarter loss per share of 24 cents, missing the&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43523593/peloton-interactive-inc-reports-second-quarter-fiscal-2025-financial-results" rel="noreferrer noopener">street view of an 18-cent loss</a>. Quarterly sales of $673.90 million outpaced the analyst <a target="_blank" href="https://www.benzinga.com/25/02/43535827/peloton-struggles-with-q2-losses-but-beats-sales-estimates-amid-strong-subscription-revenue-growth" rel="noreferrer noopener">consensus estimate of $654.036 million.</a>
Anmuth expressed optimism about Peloton&#8217;s second-quarter performance, noting profitability improvements, declining operating expenses, and a stronger balance sheet, but emphasized the need for a return to subscriber growth, which the company doesn&#8217;t expect in the second half of 2025.
Read More:&nbsp;<a target="_blank" href="https://www.benzinga.com/25/02/43516681/doge-gains-access-to-medicare-and-medicaid-systems-elon-musk-says-this-is-where-the-big-money-fraud-is-happening" rel="noreferrer noopener">DOGE Gains Access To Medicare And Medicaid Systems: Elon Musk Says, &#8216;This Is Where The Big Money Fraud Is Happening&#8217;</a>
Peloton expects FY25 revenue between $2.43 billion and $2.48 billion, compared to the $2.47 billion estimate. The company mentioned that this reflects a narrower range and&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">an increase of $5 million at the midpoint.</a>
The analyst sees a positive market reaction to Peloton&#8217;s raised FY25 guidance for Adj. EBITDA and free cash flow, while seeking further insights on growth prospects under new CEO Peter Stern.
The analyst noted that Peloton faced inventory constraints for Tread+ due to higher demand, which caused delays in some deliveries to third quarter.
Digital subscriptions fell by around 4k quarter-over-quarter to approximately 579k, aligning with company&#8217;s guidance and market expectations, while Strength+ surpassed 220k monthly active users.
Anmuth noted that the company&#8217;s second-quarter gross margin reached 47.2%, exceeding both the company&#8217;s guidance and market expectations.
Price Action: PTON shares are trading higher by 8.88% to $8.253 at last check Thursday.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/news/25/02/43497170/ex-spacex-engineer-with-musk-ties-granted-high-level-treasury-access-lawmakers-raise-red-flags" target="_blank" rel="noreferrer noopener">Ex-SpaceX Engineer With Musk Ties Granted High-Level Treasury Access — Lawmakers Raise Red Flags</a></li>
</ul>
Photo Courtesy: Koshiro K On Shutterstock.com.

Analyst Color

Equities

Reiteration

Analyst Ratings

General

PTON

Peloton Q2 Beats On Sales, But JP Morgan Says Long-Term Growth Hinges On Subscriber Comeback

Calamos Investments has kicked off February with a solid addition to its lineup of <a href="https://www.benzinga.com/etfs">structured protection ETFs</a>. On February 3, the firm introduced the Calamos S&amp;P 500 Structured Alt Protection ETF – February (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPSF#NYSE">CPSF</a>), an actively managed fund aiming to provide upside returns correlated to the S&amp;P 500. Along with this, the strategy is also to provide a protective buffer against downside risk.
The ETF&#8217;s &#8220;FLEX options&#8221; balance market engagement with capital loss reduction, ensuring investors can capitalize on gains while managing risk.
CPSF offers full downside protection over its one-year outcome period, excluding fees and expenses. The fund carries a net expense ratio of 69 basis points.
Also Read: <a href="https://www.benzinga.com/25/02/43534399/schwab-expands-active-fixed-income-lineup-with-new-core-bond-etf">Schwab Expands Active Fixed Income Lineup With New Core Bond ETF</a>
At the conclusion of each outcome period, CPSF will rejig its selection of FLEX options. This ensures that the upside cap may vary across different periods, adapting to market conditions.
CPSF is ideal for large-cap investors seeking risk-managed exposure to the S&amp;P 500. The fund enables investors to stay engaged in equities while reducing volatility.
CPSF joins Calamos' expanding suite of Structured Protection ETFs, which debuted with the Calamos S&amp;P 500 Structured Alt Protection ETF – May (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPSM#NYSE">CPSM</a>) in 2024. These monthly ETF releases are helping Calamos to continue introducing structured solutions that balance upside potential with risk control.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/etfs/specialty-etfs/25/02/43537016/donald-trump-once-said-bitcoin-was-based-on-thin-air-now-his-media-company-is-launching-btc-etf">Donald Trump Once Said Bitcoin &#8216;Was Based On Thin Air,&#8217; Now His Media Company Is Launching BTC ETF</a></li>
</ul>
Photo: Shutterstock

New ETFs

ETFs

CPSF

CPSM

Calamos' New CPSF ETF Offers Growth With A Safety Net

In his debut memoir &#8220;Source Code,&#8221; which hit the bookshelves on Feb. 4, <a href="https://www.benzinga.com/topic/bill-gates">Bill Gates</a> shared several stories about his teenage experiences with cannabis, alcohol and LSD. He smoked weed in high school to "look cool" and impress the girls. "It didn't work out,&#8221; he said, &#8220;but I tried.&#8221; 
Gates laid the blame for the LSD trips, of which there were at least a half-dozen, and his cannabis consumption on his best friend, the late Microsoft co-founder Paul Allen and Jimi Hendrix.
&nbsp;"Everything I did, I'm blaming it on him and Jimi Hendrix," Gates <a href="https://people.com/bill-gates-gets-candid-about-getting-drunk-and-taking-lsd-first-time-memoir-8780649">told</a> People Magazine.
The Microsoft  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) founder said Allen introduced him to &#8220;sex, drugs and rock ‘n' roll&#8221; and apparently Jimi Hendrix provided the soundtrack.
"He was far more well-versed than I was in all three, which is to say that I hadn't tried the first two and knew almost nothing about the third," Gates wrote about Allen and their high school adventures in Seattle, Washington. 
One such adventure included the first time he took LSD and how the psychedelic effects went on for a bit too long. "Part of the trip was exhilarating," Gates said but it was less fun when he was still "feeling its effects" in the dentist's chair the following day.
<h2 class="wp-block-heading">The Challenge And Benefits Of Risk-Taking</h2>
"Paul always got a kick out of challenging the things like [not] drinking. And he gave me a bunch of whiskey, which I still don't like the taste of, because that first night I drank too much," Gates said of Allen who was two years ahead of him in school. Gates graduated high school in 1973.
"I'm a huge risk-taker willing to try new things, but I also like my mind working well. And so, both during those trips and even after, you wonder, ‘Hey, did I scramble up my mind?&#8217;"
<h2 class="wp-block-heading">Profound Thoughts While Tripping On Acid? Not Really</h2>
Gates said he gave up LSD when he was about 21. Ten years later, he would become the world youngest billionaire. 
When Microsoft went public in 1986, Gates owned 45% of the company&#8217;s shares. The following year, its stock price surged, <a href="https://www.forbes.com/sites/rachelsandler/2021/10/05/for-first-time-in-30-years-bill-gates-isnt-the-no-1-or-no-2-richest-person-in-america/">according</a> to Forbes, making Gates a billionaire, worth $1.25 billion. That probably impressed the girls.
"And I'm definitely not recommending that because even though you think some of your thoughts are profound, in retrospect, they're not," he said.
Gates, now 69, continues to be open about the benefits of cannabis.
In a 2023 <a href="https://www.benzinga.com/markets/cannabis/23/07/33482267/seth-rogen-and-bill-gates-discuss-cannabis-alzheimer-and-mental-health-in-new-podcast">podcast conversation</a> with actor/weed entrepreneur Seth Rogen about mental health, Alzheimers and cannabis, Gates said it was "amazing" how marijuana policy and culture have evolved since his high school days. Over the years, Gates has expressed <a href="https://thehill.com/policy/technology/196100-bill-gates-voted-to-legalize-marijuana/">positive views</a> about the importance of cannabis reform.
Read Now:
<ul>
<li><a href="https://www.benzinga.com/tech/25/01/43218782/bill-gates-i-would-probably-be-diagnosed-on-the-autism-spectrum-if-growing-up-today">Bill Gates: &#8216;I Would Probably Be Diagnosed on the Autism Spectrum&#8217; if Growing Up Today</a></li>
</ul>
Photo: Shutterstock

Cannabis

Entertainment

Psychedelics

MSFT

Bill Gates Reflects On LSD, Cannabis, Risk-Taking And Influence Of Paul Allen And Jimi Hendrix

Investors might want to bet on Cal-Maine Foods (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/calm#NASDAQ">CALM</a>), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.
The Zacks rating relies solely on a company&#39;s changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.
The power of a changing earnings picture in determining near-term stock price movements makes the Zacks rating system highly useful for individual investors since it can be difficult to make decisions based on rating upgrades by Wall Street analysts. These are mostly driven by subjective factors that are hard to see and measure in real-time.
As such, the Zacks rating upgrade for Cal-Maine is essentially a positive comment on its earnings outlook that could have a favorable impact on its stock price.
<h2>Most Powerful Force Impacting Stock Prices</h2>
The change in a company&#39;s future earnings potential, as reflected in earnings estimate revisions, and the near-term price movement of its stock are proven to be strongly correlated. The influence of institutional investors has a partial contribution to this relationship, as these big professionals use earnings and earnings estimates to calculate the fair value of a company&#39;s shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their transaction of large amounts of shares then leads to price movement for the stock.
Fundamentally speaking, rising earnings estimates and the consequent rating upgrade for Cal-Maine imply an improvement in the company&#39;s underlying business. Investors should show their appreciation for this improving business trend by pushing the stock higher.
<h2>Harnessing the Power of Earnings Estimate Revisions</h2>
As empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, tracking such revisions for making an investment decision could be truly rewarding. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions.
The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see <a href="https://www.zacks.com/stocks/buy-list/?ADID=zp_1link&amp;ICID=zpi _1link" target="_blank">the complete list of today&#39;s Zacks #1 Rank (Strong Buy) stocks here &gt;&gt;&gt;&gt;</a>.
<h2>Earnings Estimate Revisions for Cal-Maine</h2>
This egg producer is expected to earn $15.59 per share for the fiscal year ending May 2025, which represents a year-over-year change of 174%.
Analysts have been steadily raising their estimates for Cal-Maine. Over the past three months, the Zacks Consensus Estimate for the company has increased 82.6%.
<h2>Bottom Line</h2>
Unlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of &#39;buy&#39; and &#39;sell&#39; ratings for its entire universe of more than 4000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a &#39;Strong Buy&#39; rating and the next 15% get a &#39;Buy&#39; rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term.
You can learn <a href="https://www.zacks.com/education/stock-education/zacks-rank-guide" target="_blank">more about the Zacks Rank here &gt;&gt;&gt;</a>
The upgrade of Cal-Maine to a Zacks Rank #1 positions it in the top 5% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.
<h2>7 Best Stocks for the Next 30 Days</h2>
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers &quot;Most Likely for Early Price Pops.&quot;
Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.3% per year. So be sure to give these hand picked 7 your immediate attention.&nbsp;
<a href="https://www.zacks.com/registration/ultimatetrader/welcome/eoffer/4e87?add=1473&amp;adid=SYND_BENZ_ZU_7BESTREPORTA_TALEOFTAPE_523_02062025_2411437&amp;cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2411437" style="font-weight:bold">See them now &gt;&gt;</a>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. <a href="https://www.zacks.com/registration/pfp/?ALERT=RPT_7BST_LP194&amp;ADID=SYND_BENZ_7BEST_TALEOFTAPE_523_2411437&amp;cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2411437" target="_blank">Click to get this free report</a> 
<a href="https://www.zacks.com/registration/pfp?ALERT=ZER_LINK&amp;t=CALM&amp;ADID=SYND_BENZ_TCK_TALEOFTAPE_523_2411437_CALM&amp;cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2411437">Cal-Maine Foods, Inc. (NASDAQ: </a><a class="ticker" href="https://www.benzinga.com/stock/calm#NASDAQ">CALM</a>): Free Stock Analysis Report
<a href="https://www.zacks.com/stock/news/2411437/all-you-need-to-know-about-cal-maine-calm-rating-upgrade-to-strong-buy?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2411437">To read this article on Zacks.com click here.</a>
<a href="https://www.zacks.com/">Zacks Investment Research</a>
Photo via Shutterstock

Upgrades

CALM

All You Need To Know About Cal-Maine (CALM) Rating Upgrade To Strong Buy

<a href="https://www.ft.com/content/33b307b8-2d72-482a-83d8-a3371db7d3c7?shareType=nongift" title="https://www.ft.com/content/33b307b8-2d72-482a-83d8-a3371db7d3c7?shareType=nongift">https://www.ft.com/content/33b307b8-2d72-482a-83d8-a3371db7d3c7?shareType=nongift</a>

Global

LRLCF

LRLCY

ULTA

"L'Oréal Boss Says It Is 'crunch Time' For Europe To Boost Its Competitiveness" - Financial Times

The Czech Republic has officially passed a law exempting Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) holdings from <a href="https://www.benzinga.com/money/cryptocurrency-tax-guide">capital gains tax</a> if held for more than three years.
President Petr Pavel signed the bill into law, solidifying a parliamentary decision made in December.
This <a href="https://cmp.seznam.cz/nastaveni-souhlasu?service=bcr&amp;cwtime=1738858980883">change</a> aims to incentivize long-term cryptocurrency investment while aligning the country's financial policies with broader European regulations.
Under the new legislation, individuals who purchased Bitcoin before 2025 can also benefit from the tax exemption if they meet the required holding period. 
Additionally, cryptocurrency transactions under 100,000 koruna (approximately $4,100) will no longer require tax reporting. 
Previously, all crypto transactions were considered taxable, similar to policies in the United States.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43532705/arthur-hayes-blasts-strategic-bitcoin-reserve-regulatory-bill-as-net-negatives">Arthur Hayes Blasts Strategic Bitcoin Reserve, Regulatory Bill As &#8216;Net Negatives&#8217;</a>
This regulatory shift is part of the Czech Republic's efforts to integrate with the European Union's Markets in Crypto-Assets (MiCA) framework, which came into effect last year. 
The move reflects the country's growing embrace of digital assets and an effort to make taxation policies more competitive within the region.
Beyond tax reform, discussions on cryptocurrency regulation are gaining momentum in the country. 
At a recent industry conference in Prague, former Prime Minister Andrej Babiš emphasized the importance of balanced crypto regulations and fair tax policies. 
Meanwhile, the Czech National Bank is exploring the possibility of investing in digital assets. 
Governor Aleš Michl recently indicated that up to 5% of the bank's €140 billion ($146 billion) reserves could be allocated to Bitcoin as part of a broader diversification strategy.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43526178/ethereum-faces-intense-competition-from-solana-struggles-to-compete-with-bitcoin-jpmorgan">Ethereum Faces &#8216;Intense Competition&#8217; From Solana, Struggles To Compete With Bitcoin: JPMorgan</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Czech Republic Approves Bitcoin Tax Exemption For Long-Term Holders

OpenAI Exec Says Right Now There's About $175B In Capital Already Waiting To Be Allocated For AI Infrastructure; We're Trying To Anchor Somewhere Between 5 And 10 As A Campus Footprint

OpenAI Exec Says Texas Will Be The Flagship Of Stargate Project; Around 16 States Have Indicated Interest In Building Data Centers In OpenAI's Stargate Project; Construction Is Underway At Our First Site In Abilene, Texas; More Site Announcements Coming Later In The Spring; Data Center Campuses Aimed At Being One Gigawatt And Will Create Thousands Of Jobs; Handover Of First Tranche Of Data Center Compute In Abilene Later This Year

Financial giants have made a conspicuous bearish move on Visa. Our analysis of options history for Visa (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) revealed 97 unusual trades.
Delving into the details, we found 31% of traders were bullish, while 45% showed bearish tendencies. Out of all the trades we spotted, 46 were puts, with a value of $2,356,363, and 51 were calls, valued at $3,049,433.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $140.0 to $430.0 for Visa over the recent three months. 
<h3>Insights into Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Visa stands at 696.33, with a total volume reaching 5,215.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Visa, situated within the strike price corridor from $140.0 to $430.0, throughout the last 30 days.
<h3>Visa Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738869330_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>V</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$25.9</td>
<td>$25.3</td>
<td>$25.4</td>
<td>$345.00</td>
<td>$508.0K</td>
<td align="right">3</td>
<td align="right">200</td>
</tr>
<tr>
<td>V</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/17/27</td>
<td>$44.4</td>
<td>$42.5</td>
<td>$44.4</td>
<td>$380.00</td>
<td>$88.5K</td>
<td align="right">231</td>
<td align="right">56</td>
</tr>
<tr>
<td>V</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$215.55</td>
<td>$214.45</td>
<td>$215.55</td>
<td>$140.00</td>
<td>$86.2K</td>
<td align="right">72</td>
<td align="right">22</td>
</tr>
<tr>
<td>V</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$217.8</td>
<td>$215.5</td>
<td>$215.5</td>
<td>$140.00</td>
<td>$86.2K</td>
<td align="right">72</td>
<td align="right">18</td>
</tr>
<tr>
<td>V</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$217.65</td>
<td>$215.45</td>
<td>$215.45</td>
<td>$140.00</td>
<td>$86.1K</td>
<td align="right">72</td>
<td align="right">26</td>
</tr>
</tbody>
</table>

<h3>About Visa</h3>
Visa is the largest payment processor in the world. In fiscal 2023, it processed almost $15 trillion in total volume. Visa operates in over 200 countries and processes transactions in over 160 currencies. Its systems are capable of processing over 65,000 transactions per second.
<h3>Current Position of Visa</h3>
<ul>
<li>Currently trading with a volume of 2,229,241, the V's price is down by -0.63%, now at $347.24. </li>
<li>RSI readings suggest the stock is currently may be overbought.</li>
<li>Anticipated earnings release is in 75 days.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Visa, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Visa Unusual Options Activity

Whales with a lot of money to spend have taken a noticeably bullish stance on DraftKings.
Looking at options history for DraftKings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>) we detected 8 trades.
If we consider the specifics of each trade, it is accurate to state that 50% of the investors opened trades with bullish expectations and 50% with bearish.
From the overall spotted trades, 3 are puts, for a total amount of $103,433 and 5, calls, for a total amount of $342,175.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $28.0 to $48.0 for DraftKings over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for DraftKings's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across DraftKings's significant trades, within a strike price range of $28.0 to $48.0, over the past month.
<h3>DraftKings Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738869325_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DKNG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$7.85</td>
<td>$7.7</td>
<td>$7.7</td>
<td>$40.00</td>
<td>$197.1K</td>
<td>175</td>
<td>256</td>
</tr>
<tr>
<td>DKNG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$6.3</td>
<td>$6.2</td>
<td>$6.27</td>
<td>$40.00</td>
<td>$55.1K</td>
<td>1.4K</td>
<td>96</td>
</tr>
<tr>
<td>DKNG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$8.45</td>
<td>$8.35</td>
<td>$8.35</td>
<td>$48.00</td>
<td>$37.5K</td>
<td>1</td>
<td>46</td>
</tr>
<tr>
<td>DKNG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$3.1</td>
<td>$3.05</td>
<td>$3.05</td>
<td>$43.00</td>
<td>$32.9K</td>
<td>1.1K</td>
<td>108</td>
</tr>
<tr>
<td>DKNG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/07/25</td>
<td>$1.04</td>
<td>$0.99</td>
<td>$1.02</td>
<td>$41.50</td>
<td>$32.9K</td>
<td>3.5K</td>
<td>2.3K</td>
</tr>
</tbody>
</table>

<h3>About DraftKings</h3>
DraftKings got its start in 2012 as an innovator in daily fantasy sports. Then, following a Supreme Court ruling in 2018 that allowed states to legalize online sports wagering, the company expanded into online sports and casino gambling, where it generally holds the number two or three revenue share position across states in which it competes. DraftKings is now live with online or retail sports betting in about 30 states and iGaming in seven states, with both products available to around 40% of Canada's population. The company also operates a non-fungible token commissioned-based marketplace and develops and licenses online gaming products.
<h3>Where Is DraftKings Standing Right Now?</h3>
<ul>
<li>With a volume of 2,651,079, the price of DKNG is up 0.47% at $42.44. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 7 days.</li>
</ul>
<h3>What The Experts Say On DraftKings</h3>
2 market experts have recently issued ratings for this stock, with a consensus target price of $52.5.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from TD Cowen continues to hold a Buy rating for DraftKings, targeting a price of $51. 
&#x2A; An analyst from Susquehanna has decided to maintain their Positive rating on DraftKings, which currently sits at a price target of $54. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for DraftKings with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

DKNG

DraftKings's Options: A Look at What the Big Money is Thinking

Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly.
Looking at options history for Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) we detected 116 trades.
If we consider the specifics of each trade, it is accurate to state that 43% of the investors opened trades with bullish expectations and 37% with bearish.
From the overall spotted trades, 25 are puts, for a total amount of $2,073,442 and 91, calls, for a total amount of $5,734,136.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $470.0 and $1300.0 for Eli Lilly, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Eli Lilly's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Eli Lilly's whale activity within a strike price range from $470.0 to $1300.0 in the last 30 days. 
<h3>Eli Lilly Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738869320_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$418.0</td>
<td>$409.0</td>
<td>$412.6</td>
<td>$480.00</td>
<td>$825.2K</td>
<td>34</td>
<td align="right">20</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$132.65</td>
<td>$130.95</td>
<td>$130.95</td>
<td>$940.00</td>
<td>$629.1K</td>
<td>193</td>
<td align="right">49</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$69.0</td>
<td>$66.95</td>
<td>$69.0</td>
<td>$880.00</td>
<td>$207.0K</td>
<td>10</td>
<td align="right">57</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$19.95</td>
<td>$19.55</td>
<td>$19.95</td>
<td>$880.00</td>
<td>$179.7K</td>
<td>1.4K</td>
<td align="right">680</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$31.65</td>
<td>$30.15</td>
<td>$30.15</td>
<td>$800.00</td>
<td>$117.5K</td>
<td>725</td>
<td align="right">58</td>
</tr>
</tbody>
</table>

<h3>About Eli Lilly</h3>
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
After a thorough review of the options trading surrounding Eli Lilly, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Present Market Standing of Eli Lilly</h3>
<ul>
<li>Trading volume stands at 4,662,591, with LLY's price up by 3.71%, positioned at $873.4.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 0 days.</li>
</ul>
<h3>Professional Analyst Ratings for Eli Lilly</h3>
3 market experts have recently issued ratings for this stock, with a consensus target price of $1066.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Citigroup continues to hold a Buy rating for Eli Lilly, targeting a price of $1190. 
&#x2A; An analyst from Wells Fargo has decided to maintain their Overweight rating on Eli Lilly, which currently sits at a price target of $970. 
&#x2A; Consistent in their evaluation, an analyst from Truist Securities keeps a Buy rating on Eli Lilly with a target price of $1038. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Eli Lilly with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

A Closer Look at Eli Lilly's Options Market Dynamics

Canopy Gwth Option Alert: Jun 20 $4 Calls Sweep (12) Near The Ask: 1693 @ $0.43 vs 3974 OI; Earnings 2/7 Before Open Ref=$2.73

WIIM

PAHC

Phibro Animal Health shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY25 guidance.

Mach Natural Resources shares are trading lower after the company announced an offering of 12,903,226 shares.

AMTD

AMTD Digital shares are trading higher after the company announced a partnership with Alibaba Pictures Culture for firm, entertainment, and fashion.

Thornburg Investment Management is spreading its roots in the ETF space with the launch of two <a href="https://www.benzinga.com/etfs">actively managed bond funds</a>.
The Thornburg Core Plus Bond ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPLS#NYSE">TPLS</a>) and the Thornburg Multi Sector Bond ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMB#NYSE">TMB</a>) aim to provide investors with diversified bond market exposure through strategic, active management.
The latest launches build on Thornburg's growing ETF footprint. Just last month, the firm <a href="https://www.benzinga.com/25/01/43200794/thornburgs-etf-debut-first-funds-target-global-equities-with-active-strategies">introduced its first two actively managed ETFs</a>, the Thornburg International Equity ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXUE#NASDAQ">TXUE</a>) and the Thornburg International Growth ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXUG#NASDAQ">TXUG</a>). These funds have already attracted more than $80 million in investments.
Also Read: <a href="https://www.benzinga.com/25/02/43537127/cohen-steers-expands-active-etf-offerings-with-three-new-funds">Cohen &amp; Steers Expands Active ETF Offerings With Three New Funds</a>
"With over $80 million in client inflows, it's clear that investors look to Thornburg's four decades of investing excellence and prudent risk management to achieve their long-term financial goals," said Mark Zinkula, CEO of Thornburg Investment Management. "Expanding our ETF lineup with two fixed-income ETFs reflects our commitment to meeting long-term client demand."
<h3 class="wp-block-heading">Disciplined Investment With TPLS</h3>
The Thornburg Core Plus Bond ETF is designed to provide income and capital appreciation with flexibility to invest in a broad range of bonds and related instruments. The net expense ratio of 45 basis points.
Up to 25% of the ETF&#8217;s net assets can be allocated to high-yield bonds, offering the potential for higher income and diversification.
<h3 class="wp-block-heading">Expanding Sector Exposure With TMB</h3>
The Thornburg Multi Sector Bond ETF is ideal for investors seeking broader exposure to fixed-income markets. With a net expense ratio of 0.55%, TMB invests in various fixed-income securities, including mortgage-backed securities, structured notes, bank loans, and zero-coupon bonds.
Like TPLS, it seeks to generate both income and capital appreciation. It does so through a more extensive selection of fixed-income assets.
As demand for actively managed bond funds grows, Thornburg's latest ETFs provide additional tools for portfolio diversification and income generation. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43534399/schwab-expands-active-fixed-income-lineup-with-new-core-bond-etf">Schwab Expands Active Fixed Income Lineup With New Core Bond ETF</a></li>
</ul>
Photo: Shutterstock

TPLS

TXUE

TXUG

Thornburg's New Bond ETF Launches: A Peek Into TPLS And TMB

New York lawmakers have introduced a <a href="https://www.nysenate.gov/legislation/bills/2025/S3600">bill</a> aimed at decriminalizing the possession of controlled substances, a move that could reshape drug policy in the state. Senate Bill S3600, sponsored by State Senator Gustavo Rivera (D-WF, 33rd District), seeks to eliminate criminal and civil penalties for personal drug possession, prioritizing public health over punishment. The bill also proposes the creation of a Drug Decriminalization Task Force to develop further recommendations for reforming laws and regulations related to drug use and substance use disorder (SUD).
<h3 class="wp-block-heading">A Paradigm Shift In Drug Policy</h3>
If enacted, S3600 would repeal key sections of New York's penal code that criminalize drug possession. It would expunge past convictions and ensure that individuals on parole, probation or awaiting trial are not penalized for conduct that is no longer criminal under the new law. Instead of facing misdemeanor charges, individuals caught with small amounts of controlled substances would receive a fine of up to $50 or be referred to a screening for social services, including substance use treatment, housing assistance or mental health support.
"The purpose of this legislation is to save lives and to help transform New York's approach to drug use from one based on criminalization and stigma to one based on science and compassion," the bill states.
<h3 class="wp-block-heading">Case For Decriminalization</h3>
New York's move follows a growing global trend of drug decriminalization policies aimed at reducing incarceration rates and promoting harm reduction. Portugal, which decriminalized drug possession in 2001, saw a <a href="https://www.unaids.org/en/resources/presscentre/featurestories/2020/march/20200303_drugs">dramatic drop</a> in overdose deaths and HIV infections among people who use drugs. Other countries, including the <a href="https://globalinitiative.net/wp-content/uploads/2017/12/GCDP-Report-2016-ENGLISH.pdf">Netherlands</a>, <a href="https://www.unodc.org/documents/ungass2016/Contributions/Civil/DrugPolicyAlliance/DPA_Fact_Sheet_Approaches_to_Decriminalization_Feb2015_1.pdf">Argentina</a>, Colombia and <a href="https://www.wola.org/sites/default/files/Drug%20Policy/IDPC-briefing-paper_Drug-policy-reform-in-Latin-America_V2_ENGLISH.pdf">Mexico</a>, have adopted similar models.
In the United States, <a href="https://www.npr.org/2021/06/18/1007022652/oregons-pioneering-drug-decriminalization-experiment-is-now-facing-the-hard-test">Oregon</a> became the first state to decriminalize all drugs in 2020, passing Measure 110, which redirected law enforcement funding toward treatment and harm reduction services. While Oregon's policy has faced scrutiny over implementation challenges, advocates argue that it is still a step in the right direction, away from the failed War on Drugs.
<h3 class="wp-block-heading">Role Of Drug Decriminalization Task Force</h3>
A key component of New York's bill is the establishment of a Drug Decriminalization Task Force, which would be responsible for analyzing drug use trends, identifying effective public health strategies and proposing additional legal reforms. The task force would examine:
<ul>
<li>The quantities of drugs considered consistent with personal use.</li>
<li>The barriers people with SUD face in accessing treatment.</li>
<li>How to mitigate the collateral consequences of drug-related convictions, such as restrictions on employment, housing and education.</li>
</ul>
The bill explicitly addresses racial disparities in drug law enforcement, acknowledging that Black and Latinx communities have historically been disproportionately affected by drug-related arrests and incarceration rates.
<h3 class="wp-block-heading">Public Health vs. Criminalization</h3>
The shift toward decriminalization aligns with the growing consensus among health experts that SUD is a medical condition, not a moral failing. The National Institute on Drug Abuse (NIDA) describes substance use disorder as "a chronic, relapsing disorder that leads to lasting changes in the brain, characterized by compulsive drug-seeking behavior." Research suggests that punitive drug policies have done little to deter drug use but have exacerbated the stigma and barriers to care for those struggling with addiction.
Advocates argue that treating drug use as a health issue rather than a crime would not only reduce incarceration rates but also help curb overdose deaths, lower HIV and hepatitis transmission rates and improve access to treatment.
<h3 class="wp-block-heading">Potential Challenges And Criticism</h3>
Despite its ambitious goals, S3600 is likely to face opposition from law enforcement groups as well as some policymakers and concerned citizens who fear decriminalization could lead to increased drug use and public safety issues. Critics point to Oregon's initial struggles with Measure 110, where a lack of treatment infrastructure and public confusion about the law's implementation slowed its impact.
However, supporters argue that New York can learn from Oregon's challenges by ensuring adequate investment in treatment services before fully implementing decriminalization.
<h3 class="wp-block-heading">What Comes Next?</h3>
Senate Bill S3600 is now under review in the Senate Codes Committee. If it advances, the next steps include:
<ul>
<li>On Floor Calendar Assembly</li>
<li>On Floor Calendar Senate</li>
<li>Passed Assembly</li>
<li>Passed Senate</li>
<li>Delivered to Governor</li>
<li>Signed By Governor</li>
</ul>
If the bill successfully navigates these steps, it would mark a significant shift in how New York addresses drug use and substance dependency. As New York debates the merits of decriminalization, one thing is clear: the conversation around drug policy is shifting, and with it the potential for a more health-focused, harm-reduction-driven approach to addressing substance use.
Photo via Shutterstock

Politics

Inside New York's Bold Plan To Decriminalize Drug Possession

SGBX

Safe & Green Holdings Shares Resume Trade

Macro Economic Events

Econ #s

Economics

Bank of Mexico Cuts Overnight Rate 50 Bps To 9.50%

LYFT

Lyft shares are trading higher after the company announced it will work with Anthropic to create new Lyft products to change the rideshare experience.

Moleculin Biotech ( ($MBRX) ) just unveiled an announcement. Moleculin Biotech has revealed promising findings showcasing Annamycin's potential to ...

Moleculin Biotech Advances Annamycin for AML Treatment

Moleculin Biotech ( ($MBRX) ) has issued an update. Moleculin Biotech, Inc. announced the use of a new corporate presentation on November 18, 2024,...

Moleculin Biotech Unveils New Corporate Presentation

Moleculin Biotech ( ($MBRX) ) has provided an update. Moleculin Biotech announced the online publication of preclinical data showing significant ac...

Moleculin Biotech files for stock and warrants offering

17:04 EST Moleculin Biotech (MBRX) files to sell common stock, warrants, no amount given Published first on TheFly – the ultimate source for real-t...

Moleculin Biotech files to sell common stock, warrants, no amount given

Moleculin Biotech ( ($MBRX) ) has issued an update. Moleculin Biotech, Inc. announced the use of a corporate presentation as part of its communicat...

Moleculin Biotech Shares Corporate Presentation Update

Moleculin Biotech ( ($MBRX) ) has provided an update. Moleculin Biotech announced significant progress in the development of its drug Annamycin, pa...

Moleculin Biotech Advances Annamycin to Phase 3 Trial

In a report released on January 10, Jonathan Aschoff from Roth MKM assigned a Buy rating to Moleculin Biotech (MBRX – Research Report), with a pric...

Moleculin Biotech (MBRX) Gets a Buy from Roth MKM

The latest update is out from Moleculin Biotech ( ($MBRX) ). On January 27, 2025, Moleculin Biotech announced that its CEO, Walter Klemp, participa...

Moleculin Biotech Shares Updates on MIRACLE Trial

The latest update is out from Moleculin Biotech ( ($MBRX) ). On January 27, 2025, Moleculin Biotech announced the launch of its MIRACLE pivotal stu...

Moleculin Biotech Launches MIRACLE Study for AML

Small Cap

Press Releases

Transcript from Moleculin's Recent Virtual Acute Myeloid Leukemia KOL Event Now Available

Moleculin Appoints Leading Expert in Pancreatic Cancer to its Scientific Advisory Board to Support Development of Annamycin

Moleculin to Report Third Quarter 2024 Financial Results on November 8, 2024 and Host Conference Call and Webcast

Earnings

Moleculin Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Moleculin Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin in Combination with Cytarabine for the Treatment of R/R Acute Myeloid Leukemia (AML)

Moleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025

New Findings Show Moleculin's Annamycin Overcomes Resistance to Venetoclax in AML

Moleculin Announces Online Publication of Preclinical Data Demonstrating Significant Activity of Annamycin in Venetoclax Resistant AML Model

Moleculin Highlights Development Progress of Annamycin, Phase 2 Data Outperforms Billion-Dollar Assets in AML, Phase 3 Data Readouts in 2025 & 2026

Comments

Moleculin Biotech

Noticias

Últimas noticias sobre Moleculin Biotech (NASDAQ:MBRX) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL